StreetInsider.com News Articles

Form 4 Evolent Health, Inc. For: Aug 26 Filed by: McCarthy Daniel Joseph

Fri, 28 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260828/26998201.html

Form 4 Evolent Health, Inc. For: Aug 26 Filed by: McCarthy Daniel Joseph

Fri, 28 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260828/26998201.html

Form 144 Evolent Health, Inc. Filed by: McCarthy Daniel Joseph

Wed, 26 Aug 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260826/26983021.html

Form 144 Evolent Health, Inc. Filed by: McCarthy Daniel Joseph

Wed, 26 Aug 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260826/26983021.html

Evolent Health (EVH) PT Raised to $6 at JPMorgan

Tue, 18 Aug 2026 08:44:07 -0400

JPMorgan analyst John Stansel raised the price target on Evolent Health (NYSE: EVH) to $6.00 (from $5.00) while maintaining a Overweight rating.

Evolent Health (EVH) PT Raised to $6 at TD Cowen

Mon, 17 Aug 2026 08:11:37 -0400

TD Cowen analyst Charles Rhyee raised the price target on Evolent Health (NYSE: EVH) to $6.00 (from $5.00) while maintaining a Buy rating.

Evolent Health (EVH) PT Lowered to $6 at Truist Securities

Wed, 12 Aug 2026 05:09:27 -0400

Truist Securities analyst Jailendra Singh lowered the price target on Evolent Health (NYSE: EVH) to $6.00 (from $7.00) while maintaining a Hold rating.

The analyst comments "We are incrementally more constructive on EVH following 2Q results and our subsequent management discussion. The addition of the $300 million oncology contract, together with the annualization of Highmark and the ramp of other signed agreements, provides greater visibility into the company’s approximately 25% revenue growth framework for 2027 and reinforces the strength of demand for its Performance Suite offering. More importantly, we view the $150 million 2027 adjusted EBITDA midpoint as increasingly derisked. The

Evolent Health (EVH) PT Lowered to $6 at Truist Securities

Wed, 12 Aug 2026 05:09:27 -0400

Truist Securities analyst Jailendra Singh lowered the price target on Evolent Health (NYSE: EVH) to $6.00 (from $7.00) while maintaining a Hold rating.

Citi Upgrades Evolent Health (EVH) to Buy

Mon, 10 Aug 2026 16:09:05 -0400

Citi analyst Daniel Grosslight upgraded Evolent Health (NYSE: EVH) from Neutral to Buy with a price target of $6.00 (from $6.75).

For an analyst ratings summary and ratings history on Evolent Health click here. For more ratings news on Evolent Health click here.

Shares of Evolent Health closed at $3.95 yesterday.

Evolent Health (EVH) PT Lowered to $6 at Canaccord

Mon, 10 Aug 2026 07:34:02 -0400

(Updated - August 10, 2026 7:34 AM EDT)

Canaccord analyst Richard Close lowered the price target on Evolent Health (NYSE: EVH) to $6.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "2Q was solid, with revenue topping CGe/Consensus by 10.5%/9.2% and adj-EBITDA eclipsing CGe/Consensu by 24.5%/22.9%. Looking forward, revenue guidance was raised, while the adj-EBITDA range was tightened. Management commentary on increasing confidence combined with expectation of 93% MER was encouraging, especially given the challenging environment in ACA and Medicaid. New business wins has not been a problem for Evolent and that continued with several deals announced with existing clients

Evolent Health (EVH) PT Lowered to $6 at Canaccord

Mon, 10 Aug 2026 07:34:02 -0400

(Updated - August 10, 2026 7:34 AM EDT)

Canaccord analyst Richard Close lowered the price target on Evolent Health (NYSE: EVH) to $6.00 (from $7.00) while maintaining a Buy rating.

Form 10-Q Evolent Health, Inc. For: Jun 30

Thu, 06 Aug 2026 08:54:00 -0400

si-local-file:///var/storage/secattach/20260806/26880165.html

Form 10-Q Evolent Health, Inc. For: Jun 30

Thu, 06 Aug 2026 08:54:00 -0400

si-local-file:///var/storage/secattach/20260806/26880165.html

Evolent Health (EVH) Tops Q2 EPS by 3c

Thu, 06 Aug 2026 07:06:31 -0400

Evolent Health (NYSE: EVH) reported Q2 EPS of $0.02, $0.03 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $652.52 million versus the consensus estimate of $597.46 million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

Form 8-K Evolent Health, Inc. For: Aug 06

Thu, 06 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26878474.html

Form 8-K Evolent Health, Inc. For: Aug 06

Thu, 06 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26878474.html

Evolent Announces Second Quarter 2026 Results